Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Riliprubart - Sanofi

Next Previous
Drug Profile

Riliprubart - Sanofi

Alternative Names: BIVV-020; SAR-445088; TNT-020

Latest Information Update: 07 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; Sanofi; Sanofi-Aventis Recherche & Developpement
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Idiopathic thrombocytopenic purpura; Renal transplant rejection
  • Discontinued Autoimmune haemolytic anaemia

Most Recent Events

  • 30 Jun 2025 Riliprubart - Sanofi receives Orphan Drug status for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan
  • 01 Apr 2025 Phase-III clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (Treatment-experienced) in Canada and China (SC) (NCT06859099)
  • 05 Mar 2025 Sanofi plans a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy (SC, Injection) in April 2025 (NCT06859099, EudraCT2024-517032-22-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top